LENZ
LENZ Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Strong Buy
1.3 / 5
7 analysts
$5.79
+$0.11 (+1.94%)
Target:
$32.00
(452.7%)
Sign in to add LENZ to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $181.54M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.67 |
| EPS (TTM) | $-3.64 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -49.71% |
| Debt/Equity | 0.27 |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $32.00 |
| Analysts | 7 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 31.8 |
| Beta | 1.47 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $50.40 |
| 52-Week Low | $5.23 |
| 50-Day Avg | $7.61 |
| 200-Day Avg | $18.66 |
| Avg Volume | 781.3K |
| Volume | 522.9K |
Performance Analysis
BULLISHLENZ shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($5.23), which could present a value opportunity.
~
RSI at 31.8 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Wall Street consensus is "Strong Buy" from 7 analysts.
+
Average analyst target of $32.00 implies 452.7% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:18 UTC
Back to Screener Export Report